<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>SPRINT Trial – Statistical Review</title>

  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-VSJE2TEEHZ"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    gtag('config', 'G-VSJE2TEEHZ');
  </script>

  <!-- SEO -->
  <meta name="description" content="Statistical and methodological critique of the SPRINT trial.">
  <meta name="keywords" content="SPRINT trial, hypertension, SBP target, blood pressure, clinical trial design, type I error, The Data Guru">
  <meta name="author" content="W. R. Long">

  <!-- Open Graph -->
  <meta property="og:title" content="SPRINT Trial Review | The Data Guru">
  <meta property="og:description" content="Statistical and methodological critique of the SPRINT trial.">
  <meta property="og:image" content="https://thedataguru.net/images/medium_resolution_logo.png">
  <meta property="og:url" content="https://thedataguru.net/stat-reviews/sprint/">
  <meta property="og:type" content="article">

  <!-- Twitter -->
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="SPRINT Trial Review | The Data Guru">
  <meta name="twitter:description" content="Statistical and methodological critique of the SPRINT trial.">
  <meta name="twitter:image" content="https://thedataguru.net/images/medium_resolution_logo.png">

  <!-- Fonts + CSS -->
  <link href="https://fonts.googleapis.com/css?family=Montserrat:300,400,600" rel="stylesheet">
  <link rel="stylesheet" href="/css/stat-reviews.css" />
</head>

<body>

<a href="/"><img src="/images/medium_resolution_logo.png" alt="The Data Guru Logo" class="logo"></a>
<p class="tagline">Statistical and Methodological Reviews for Cardiologists</p>

<!-- BEGIN SPRINT REVIEW HTML -->

<h1>Review and Statistical Critique of the SPRINT Trial</h1>

<p><strong>Reviewer:</strong> Robert Long<br>
<strong>Position:</strong> Principal Consultant<br>
<strong>Company:</strong> The Data Guru Ltd<br>
<strong>Date:</strong> 18 May 2025<br>
<strong>Document Version:</strong> 1.5</p>

<hr>

<h2>I. Introduction & Background</h2>

<p>The <strong>SPRINT</strong> trial, published by Wright et al. (2015), was a landmark randomised controlled trial (RCT) investigating whether systolic blood pressure (SBP) targets for high-risk, non-diabetic patients should be lowered to &lt;120 mm Hg rather than the traditional &lt;140 mm Hg.</p>

<p>At the time, international guidelines varied considerably, driven by inconclusive evidence from earlier trials such as ACCORD-BP (2010) and HYVET (2008). SPRINT influenced guidelines in the United States, recommending stricter SBP control (&lt;130 mm Hg).</p>

<p>This review critically evaluates the trial’s statistical methods, design, outcomes, and implications. It draws upon primary and ancillary trial publications, meta-analyses, and key reappraisals, notably Wright et al. (2021), who address several methodological criticisms.</p>

<h2>II. Trial Design and Methodology</h2>

<p>SPRINT was a publicly funded, multi-centre, open-label RCT with blinded outcome adjudication. It was conducted at 102 clinical sites in the US and enrolled 9,361 participants aged ≥50 years at elevated cardiovascular risk. Key exclusions included diabetes mellitus and prior stroke.</p>

<p><strong>Randomised groups:</strong></p>
<ul>
  <li><strong>Intensive treatment:</strong> SBP target &lt;120 mm Hg</li>
  <li><strong>Standard treatment:</strong> SBP target &lt;140 mm Hg</li>
</ul>

<p>Blood pressure was measured using the Omron HEM-907XL device. Most readings were taken unattended to reduce white-coat effects.</p>

<h3>Inclusion Criteria</h3>
<ul>
  <li>Age ≥50 years</li>
  <li>SBP 130–180 mm Hg</li>
  <li>At least one CV risk factor (e.g., CVD, CKD, age ≥75, Framingham 10-year risk ≥15%)</li>
</ul>

<h3>Exclusion Criteria</h3>
<ul>
  <li>Diabetes mellitus</li>
  <li>Prior stroke</li>
  <li>LVEF &lt;35% or symptomatic heart failure</li>
  <li>Significant proteinuria</li>
</ul>

<p>The trial was stopped early (median follow-up: 3.26 years) due to observed benefit.</p>

<h2>III. Main Findings and Outcomes</h2>

<p><strong>Primary composite outcome:</strong></p>
<ul>
  <li>HR = 0.75, 95% CI [0.64, 0.89], p &lt; 0.001</li>
</ul>

<p><strong>All-cause mortality:</strong></p>
<ul>
  <li>HR = 0.73, 95% CI [0.60, 0.90], p = 0.004</li>
</ul>

<h3>Secondary Outcomes</h3>
<ul>
  <li>Reduced heart failure and CV death</li>
  <li>No significant difference in stroke</li>
  <li>More incident CKD (reversible)</li>
  <li>Mild cognitive impairment reduced, but no effect on dementia</li>
</ul>

<h2>IV. Critical Appraisal</h2>

<h3>Internal Validity</h3>
<ul>
  <li>Randomisation and blinding robust</li>
  <li>Outcomes adjudicated blind to group</li>
  <li>Early stopping may overstate effect size</li>
</ul>

<h3>External Validity</h3>
<ul>
  <li>Exclusions reduce generalisability (no diabetes, prior stroke)</li>
  <li>Low representation of frail/elderly</li>
</ul>

<h3>Composite Outcome Bias</h3>
<p>Effects were mainly driven by heart failure and CV death, not evenly across all endpoints.</p>

<h3>Harms</h3>
<ul>
  <li>Increased adverse events: hypotension, syncope, AKI</li>
</ul>

<h3>Blood Pressure Measurement</h3>
<p>Unattended measurements may not reflect routine clinical care.</p>

<h2>V. Clinical and Policy Implications</h2>

<ul>
  <li>US guidelines now favour SBP &lt;130 mm Hg in high-risk patients</li>
  <li>European/UK guidelines remain cautious</li>
  <li>Implementation requires careful measurement and individualised plans</li>
</ul>

<h2>VI. Conclusions</h2>

<p>SPRINT was robust and influential. Its results support lower SBP targets for selected patients, but generalisability and risk–benefit trade-offs must be carefully considered in clinical implementation.</p>

<h2>References</h2>
<ul>
  <li>Wright et al. (2015). NEJM 373(22), 2103–2116. DOI: <a href="https://doi.org/10.1056/NEJMoa1511939">10.1056/NEJMoa1511939</a></li>
  <li>Williamson et al. (2019). NEJM 380(24), 1776–1786</li>
  <li>SPRINT MIND Investigators (2019). JAMA 321(6), 553–561</li>
  <li>Ambrosius et al. (2014). Clinical Trials 11(5), 532–546</li>
  <li>Hu & Chang (2021). Hypertension 78(2), 293–303</li>
</ul>

<!-- END SPRINT REVIEW -->

<p class="back-link"><a href="../index.html">← Back to Statistical Reviews Overview</a></p>

</body>
</html>